Advertisement
Review
Survival of patients with advanced, recurrent, or metastatic human papillomavirus (HPV)-associated cancer is suboptimal despite the availability of various treatment modalities. The recently developed bacteria...
Gynecologic Oncology Research and Practice 2017 4:10
Published on: 14 July 2017
Review
Immune responses to the facultative intracellular bacterium Listeria monocytogenes (Lm) are robust and well characterized. Utilized for decades as a model of host-disease immunology, Lm is well suited for use as ...
Gynecologic Oncology Research and Practice 2017 4:9
Published on: 2 June 2017
Erratum
Gynecologic Oncology Research and Practice 2017 4:8
Published on: 23 March 2017
The original article was published in Gynecologic Oncology Research and Practice 2017 4:5
Review
Bevacizumab is an important component in the treatment of various cancers, and despite guidelines recommending its use in both ovarian and cervical cancer, patient access to bevacizumab and other angiogenesis ...
Gynecologic Oncology Research and Practice 2017 4:7
Published on: 21 March 2017
Research
Palliative systemic treatment in elderly gynaecological cancer patients remains a major challenge. In recurrent ovarian cancer (ROC), treosulfan an active alkylating drug showed similar cytotoxicity whether as...
Gynecologic Oncology Research and Practice 2017 4:6
Published on: 7 March 2017
Research
Modern cervical cancer screening increasingly relies on the use of molecular techniques detecting high-risk oncogenic human papillomavirus (hr-HPV). A major challenge for developing countries like Ghana has be...
Gynecologic Oncology Research and Practice 2017 4:5
Published on: 3 March 2017
The Erratum to this article has been published in Gynecologic Oncology Research and Practice 2017 4:8
Review
Until recently our knowledge of a genetic contribution to ovarian cancer focused almost exclusively on mutations in the BRCA1/2 genes. However, through germline and tumor sequencing an understanding of the larger...
Gynecologic Oncology Research and Practice 2017 4:4
Published on: 22 February 2017
Case Report
Nivolumab is an immune checkpoint inhibitor specific for the programmed death 1 (PD-1) receptor that has led to clinical responses in many cancer types. Identifying biomarkers predictive of response to PD-1 bl...
Gynecologic Oncology Research and Practice 2017 4:3
Published on: 2 February 2017
Review
Merkel cell carcinoma is a rare and aggressive neoplasm originating from mechanoreceptor Merkel cells of the stratum basale of the epidermis. Cases affecting the vulva are exceedingly rare, with the currently ...
Gynecologic Oncology Research and Practice 2017 4:2
Published on: 25 January 2017
Research
The National Comprehensive Cancer Network (NCCN) and the Society of Gynecologic Oncology (SGO) recommend lymph node sampling (LNS) as a key component in the surgical staging of high-grade endometrial cancer. O...
Gynecologic Oncology Research and Practice 2017 4:1
Published on: 19 January 2017
Review
Endometrial carcinoma (EC) is the fourth most common cancer in women in the developed world. Classification of ECs by histomorphologic criteria has limited reproducibility and better tools are needed to distin...
Gynecologic Oncology Research and Practice 2016 3:14
Published on: 13 December 2016
Research
Genetic testing for an inherited susceptibility to cancer is an emerging technology in medical practice. Little information is currently available about physicians’ attitudes towards these tests in developing ...
Gynecologic Oncology Research and Practice 2016 3:12
Published on: 5 December 2016
Research
Chemotherapy plays a role in the treatment of endometrioid endometrial cancer (EEC); however, tumor grade may affect response. Our objective was to evaluate associations between tumor grade and in vitro chemor...
Gynecologic Oncology Research and Practice 2016 3:13
Published on: 1 December 2016
Review
The introduction of immune checkpoint inhibitors has revolutionized treatment of multiple cancers and has bolstered interest in this treatment approach. So far, emerging clinical data show limited clinical eff...
Gynecologic Oncology Research and Practice 2016 3:11
Published on: 24 November 2016
Meeting report
The Fifth Annual Advanced Course in Cytoreductive Surgery for Ovarian Cancer and Peritoneal Surface Malignancies was held at and sponsored by the Division of Gynecologic Oncology at the the University of Calif...
Gynecologic Oncology Research and Practice 2016 3:10
Published on: 24 October 2016
Review
Cervical cancer is the fourth most common cancer among women worldwide, many of who are still within their reproductive lifespan. Advances in screening and treatment have increased the 5-year survival for earl...
Gynecologic Oncology Research and Practice 2016 3:9
Published on: 21 October 2016
Review
Although cancer in general affects an aged population, a significant number of women develop cancer at childbearing age. Long-term survival rates after gynecological cancer, especially in young patients are in...
Gynecologic Oncology Research and Practice 2016 3:8
Published on: 27 July 2016
Review
The management of patients with recurrent gynecological malignancy is complex, and often contentious. While historically, patients with metastases in the lungs, liver or brain have been treated with palliative...
Gynecologic Oncology Research and Practice 2016 3:7
Published on: 17 June 2016
Research
Our objective was to determine if previously reported overall survival (OS) and progression-free survival (PFS) rates are maintained long term following multimodal therapy for advanced and recurrent endometria...
Gynecologic Oncology Research and Practice 2016 3:6
Published on: 26 May 2016
Case report
Selumetinib is a potent, selective, orally available, and non-ATP competitive small molecule inhibitor of mitogen-activated protein kinase kinase 1/2 (MEK1/2) that has demonstrated single agent activity in a n...
Gynecologic Oncology Research and Practice 2016 3:5
Published on: 5 May 2016
Research
After platinum and taxane chemotherapy, with or without bevacizumab, active regimens for advanced or recurrent cervical cancer are lacking. Our objective was to review a single institution experience in treati...
Gynecologic Oncology Research and Practice 2016 3:4
Published on: 14 April 2016
Review
Poly(ADP-ribose) polymerase (PARP), which was first described over 50 years ago by Mandel, are a family of protein enzymes involved in DNA damage response and works by recognizing the single-strand DNA break (...
Gynecologic Oncology Research and Practice 2016 3:3
Published on: 26 February 2016
Erratum
Gynecologic Oncology Research and Practice 2016 3:2
Published on: 17 February 2016
The original article was published in Gynecologic Oncology Research and Practice 2015 2:11
Research
Many women who develop endometrial cancer (EC) or endometrial hyperplasia with atypia are obese and therefore at high risk of surgical complications. Recently clinical trials have been initiated offering non-s...
Gynecologic Oncology Research and Practice 2016 3:1
Published on: 9 February 2016
Case report
Radiation induced Lumbosacral plexophaty (RILP) is a rare but severe complication that has a considerable impact on quality of life. Its occurrence is rare but increasing with improved long-term cancer surviva...
Gynecologic Oncology Research and Practice 2015 2:12
Published on: 4 December 2015
